{"protocolSection":{"identificationModule":{"nctId":"NCT07153146","orgStudyIdInfo":{"id":"PN-881-01"},"organization":{"fullName":"Protagonist Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of PN-881 in Healthy Subjects"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-10-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-22","studyFirstSubmitQcDate":"2025-08-25","studyFirstPostDateStruct":{"date":"2025-09-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-08","lastUpdatePostDateStruct":{"date":"2025-12-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Protagonist Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The goal of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PN-881 in healthy adult participants.","detailedDescription":"PN-881 will be administered in oral solution and tablet formulations, with dosing under fasting or fed conditions depending on the study part.\n\nThe study consists of five parts:\n\nPart 1 - Single Ascending Dose (SAD): Randomised, double-blind, placebo-controlled Part 2 - Multiple Ascending Dose (MAD): Randomised, double-blind, placebo-controlled Part 3 - Tablet Formulation Comparison: Open-label, crossover design; participants will receive different oral tablet formulations Part 4 - Effect of Food: Open-label, crossover design to assess the effect of food on the pharmacokinetics of PN-881. Participants will receive PN-881 tablet formulations in fasted and fed conditions.\n\nPart 5 - Dosing Frequency Comparison: Open-label, randomized study comparing once-daily and twice-daily dosing."},"conditionsModule":{"conditions":["Healthy Volunteer"],"keywords":["PN-881"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Part 1 \\& Part 2 is masked; Part 3, Part 4 and Part 5 are open label","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":142,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"PN-881 Oral Solution Single Ascending Dose","type":"EXPERIMENTAL","description":"PN-881 Oral Solution Single Ascending Dose","interventionNames":["Drug: PN-881 Oral Solution"]},{"label":"Placebo Oral Solution Single Ascending Dose","type":"PLACEBO_COMPARATOR","description":"Placebo single ascending doses","interventionNames":["Drug: Placebo"]},{"label":"PN-881 Oral Solution Multiple Ascending Dose","type":"EXPERIMENTAL","description":"PN-881 Multiple Ascending Doses","interventionNames":["Drug: PN-881 Oral Solution"]},{"label":"Placebo Oral Solution Multiple Ascending Dose","type":"PLACEBO_COMPARATOR","description":"Placebo, multiple ascending doses","interventionNames":["Drug: Placebo"]},{"label":"PN-881 Oral Tablet Single Dose","type":"EXPERIMENTAL","description":"PN-881 oral tablet single dose","interventionNames":["Drug: PN-881 Oral Tablet"]},{"label":"PN-881 Oral Tablet Multiple Dose","type":"EXPERIMENTAL","description":"PN-881 oral tablet multiple dose","interventionNames":["Drug: PN-881 Oral Tablet"]}],"interventions":[{"type":"DRUG","name":"PN-881 Oral Solution","description":"PN-881 Oral Solution","armGroupLabels":["PN-881 Oral Solution Multiple Ascending Dose","PN-881 Oral Solution Single Ascending Dose"]},{"type":"DRUG","name":"PN-881 Oral Tablet","description":"PN-881 oral tablet","armGroupLabels":["PN-881 Oral Tablet Multiple Dose","PN-881 Oral Tablet Single Dose"]},{"type":"DRUG","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo Oral Solution Multiple Ascending Dose","Placebo Oral Solution Single Ascending Dose"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence and severity of treatment-emergent adverse events (TEAEs)","description":"Evaluate the safety and tolerability of PN-881 in comparison to placebo after single and multiple doses in healthy subjects assessed for severity, seriousness, and relation to the investigational product.","timeFrame":"Predose to 7 days after last dose"}],"secondaryOutcomes":[{"measure":"Maximum observed plasma concentration (Cmax) of PN-881","description":"Highest measured plasma concentration of PN-881 following oral administration.","timeFrame":"48 hours following the first dose and the last dose"},{"measure":"Area under the plasma concentration-time curve (AUC) of PN-881","description":"AUC calculated from 0 to infinity.","timeFrame":"Predose to 48 hours after the first and last dose."},{"measure":"Levels of biomarker in serum","description":"Pharmacodynamics (PD) of PN-881 by means of increase in levels of biomarker by PN-881 after single and multiple oral doses.","timeFrame":"Day 1 Predose up to 48 hours post (last) dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy male and female participants of non-childbearing potential, aged 18-65 years inclusive\n2. Body mass index (BMI) between 18 and 32 kg/m² (inclusive) at screening\n3. Willing and able to comply with all study requirements and provide written informed consent\n4. Male participants with female partners of childbearing potential must agree to use highly effective contraception during the study and for 90 days after the last dose\n\nExclusion Criteria:\n\n1. Clinically significant history or presence of cardiovascular, gastrointestinal, hepatic, renal, neurological, psychiatric, or allergic diseases\n2. History of neoplastic disease (except adequately treated non-melanoma skin cancer)\n3. Positive test for hepatitis B, hepatitis C, or HIV at screening\n4. History of substance abuse or recreational IV drug use within the past 2 years\n5. Clinically significant infection or fever (\\>38°C) within 2 weeks prior to screening\n6. Use of any prescription/non-prescription drugs or herbal supplements within 7 days or 5 half-lives before dosing (unless approved by investigator)\n7. Supine blood pressure or ECG abnormalities outside protocol-defined ranges\n8. Use of tobacco/nicotine products exceeding 5 cigarettes/day or 2 chews/day\n9. Consumption of \\>21 alcohol units/week (males) or \\>14 units/week (females)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Study Director","role":"CONTACT","phone":"+61 1800 243 733","email":"melbourne@nucleusnetwork.com"}],"locations":[{"facility":"Nucleus Network","status":"RECRUITING","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","contacts":[{"name":"Clinical Study Director","role":"CONTACT","phone":"+61 1800 243 733","email":"melbourne@nucleusnetwork.com"}],"geoPoint":{"lat":-37.814,"lon":144.96332}}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Phase I study"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}